Prevacus, Inc. announced a partnership with blinktbi, Inc for use of their patented device, EyeStat, in Prevacus’ upcoming Phase 1 clinical research study as an objective biomarker of brain function.
TALLAHASSEE, Fla., July 13, 2018 /PRNewswire/ -- Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI) and other neurological disorders today announced a partnership with blinktbi, Inc for use of their patented device, EyeStat, in Prevacus’ upcoming Phase 1 clinical research study as an objective biomarker of brain function.
Blinktbi’s game-changing technology to be used in Prevacus’ upcoming Phase 1 drug study provides fast and objective data about neurological function by capturing and measuring the blink reflex. EyeStat is a lightweight and portable device that stimulates the blink reflex using light puffs of air in a 20 second test. High speed videography records and analyzes specific changes in the blink reflex that are indicative of traumatic brain injury, and delivers easy to read, objective data about neurological function in under one-minute.
Prevacus and blinktbi are supported in their efforts to find a solution to keep youth and professional athletes safer from the devastating effects of concussion by 3 Super Bowl MVP quarterbacks including Brett Favre, Kurt Warner and Mark Rypien. Favre, an outspoken advocate of brain health and safety after suffering what’s claimed to be thousands of concussions throughout his NFL career, said, “I commend Prevacus and blinktbi for their continued efforts in researching the harmful effects of TBI and taking measures to reduce and treat the issue.”
“EyeStat will provide significant assistance during our upcoming phase 1 clinical study,” said Dr. Jake VanLandingham, CEO of Prevacus, “We are grateful for their support in pursuit of discovering a solution to concussions for our athletes, military personnel and all other at-risk groups. It will take multiple companies collaborating to find the solve the problems of this epidemic.”
“We are thrilled to partner with Prevacus in support of the studies they’re conducting on their novel and promising drugs as an alternate line of therapies for TBI. We hope EyeStat will assist the team greatly in their studies and mission to advance treatment in this field,” stated Ryan Fiorini, Chief Operations Officer at blinktbi.
About Prevacus
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company’s first development candidate (PRV-002) represents a breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, ischemic injury and oxidative stress, visit www.prevacus.com.
About blinktbi
Blinktbi’s novel technology stimulates, records and measures the blink reflex. The device, EyeStat, uses 5 light puffs of air over 20 seconds directed near the eyelashes to trigger the blink reflex. The system employs the use of high-speed videography to record and track the eyelids while specific parameters of the blink reflex are measured using a proprietary algorithm. This process provides fast, objective data to help medical personnel with clinical assessment of brain function and decision making . Because this is based on human reflexes, test results cannot be manipulated by the patient. For more information, visit www.blinktbi.com.
About Concussion
A concussion is a type of traumatic brain injury caused by a significant force to the head or upper body causing the brain to shake inside the skull. The injury is defined as a concussion when it causes a change in mental status such as amnesia, disorientation, mental fogginess, confusion, nausea/vomiting, blurred vision, headache, balance deficits or loss of consciousness. There are 21 symptoms demonstrated to be associated with concussion. Loss of consciousness does not indicate injury severity. Because no two concussions are exactly alike, effects and recovery are sometimes difficult to assess. Therefore, the condition requires a compound that can work to reduce multiple pathological issues.
Contact
CG Capital
877.889.1972
investorrelations@cg.capital
View original content with multimedia:http://www.prnewswire.com/news-releases/prevacus-announces-use-of-blinktbis-eyestat-in-upcoming-phase-1-clinical-study-300680432.html
SOURCE Prevacus, Inc.
